20(S)-Ginsenoside Rg3 Inhibits Lung Cancer Cell Proliferation by Targeting EGFR-Mediated Ras/Raf/MEK/ERK Pathway

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Lung cancer is a leading cause of cancer mortality worldwide.
• Epidermal growth factor receptor (EGFR) is a key therapeutic target in non-small cell lung cancer (NSCLC).
• Triterpenoid saponins, including ginsenosides, show potential as anti-cancer agents.

Purpose of the Study:

• To investigate the anti-proliferative effects of 20(R)-ginsenoside Rg3 (Rg3) on NSCLC cells.
• To determine if Rg3 functions as an EGFR tyrosine kinase inhibitor (TKI).
• To elucidate the molecular mechanisms underlying Rg3's anti-cancer activity.

Main Methods:

• Quantitative real-time reverse transcription-PCR (qRT-PCR) and immunoblotting to analyze gene and protein expression.
• Cell cycle analysis to assess proliferation.
• Molecular docking and molecular dynamics simulations to study Rg3-EGFR interactions.

Main Results:

• 20(R)-ginsenoside Rg3 was confirmed as an EGFR-TKI.
• Rg3 regulates the EGFR/Ras/Raf/MEK/ERK signaling pathway.
• Rg3 treatment led to G0/G1 phase cell cycle arrest by downregulating CDK2, Cyclin A2, and Cyclin E1.
• Molecular docking and dynamics simulations indicated stable binding between Rg3 and EGFR.

Conclusions:

• 20(R)-ginsenoside Rg3 exhibits anti-proliferative effects on A549 lung cancer cells.
• Rg3 likely inhibits proliferation by arresting the cell cycle at the G0/G1 phase via the EGFR/Ras/Raf/MEK/ERK pathway.
• Rg3 represents a potential therapeutic candidate for NSCLC treatment targeting EGFR.